In the latest session, Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) closed at $1.16 down -10.08% from its previous closing price of $1.29. On the day, 3067682 shares were traded.
Ratios:
For a deeper understanding of Adaptimmune Therapeutics Plc ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.85 and its Current Ratio is at 2.85. In the meantime, Its Debt-to-Equity ratio is 0.64 whereas as Long-Term Debt/Eq ratio is at 0.50.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Bryan Garnier on March 24, 2023, initiated with a Buy rating and assigned the stock a target price of $3.60.
On January 03, 2023, Guggenheim Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $5.
Mizuho Upgraded its Neutral to Buy on November 09, 2022, while the target price for the stock was maintained at $9.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 17 ’24 when Rawcliffe Adrian sold 30,080 shares for $0.67 per share. The transaction valued at 20,244 led to the insider holds 44,848 shares of the business.
Bertrand William C JR sold 18,908 shares of ADAP for $12,725 on Jan 17 ’24. The Chief Operating Officer now owns 7,785 shares after completing the transaction at $0.67 per share. On Jan 17 ’24, another insider, Norry Elliot, who serves as the Chief Medical Officer of the company, sold 18,276 shares for $0.67 each. As a result, the insider received 12,300 and left with 7,785 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.34 while its Price-to-Book (P/B) ratio in mrq is 6.67.
Stock Price History:
Over the past 52 weeks, ADAP has reached a high of $2.05, while it has fallen to a 52-week low of $0.42.
Shares Statistics:
A total of 227.17M shares are outstanding, with a floating share count of 200.12M. Insiders hold about 11.91% of the company’s shares, while institutions hold 62.39% stake in the company.
Earnings Estimates
There are Automatic Data Processing, Inc. different market analysts currently analyzing its stock. The consensus estimate for the next quarter is $70.50, with high estimates of $3.01 and low estimates of $1.16.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Consumer Cyclical.
